Venus Remedies share news, announcements and annual reports
NSE: VENUSREMBSE: 526953Pharmaceuticals & BiotechnologySmall Cap
Venus Remedies Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995 on BSE, Dec 2006 on NSE
Last close ₹1,238.60down ₹50.70 (3.93%)BSE ₹1,231.75
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,289.30.
30 Oct: open ₹1,290.00, high ₹1,319.00, low ₹1,225.10
52-week range of traded prices to 30 Oct 2026
₹432.10Low, 31 Oct 2025₹2,044.30High, 29 Jun 2026
- Under NSE's long-term additional surveillance, stage IV, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,656 Cr1,337th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.35
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.81%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 48,127
Venus Remedies share news and announcements
697 announcements, routine notices left out, newest first. Page 14 of 14.
Sep 2008
11 Sep · Updates
"It gives us great pleasure to inform you of another land mark achievement of Venus. It is a matter of great pride for Venus Medicine Research Centre to have secured the recognition from Department of Scientific and Industrial Research (DSIR), a functionary of Ministry of Science & Technology, Government of India, New Delhi." The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Sep · Meeting
Annual General Meeting of the Company is scheduled to be held on September 22, 2008.
Aug 2008
18 Aug · Updates
The Company's manufacturing facilities have been accredited with Good Manufacturing Practices certification by the Pharmacy & Poisons Board, Ministry of Health, Kenya. The Inspectorate of MoH, Kenya had conducted a detailed inspection of the manufacturing facilities at the Baddi Campus of the Company earlier this year and found them to be compliant of all quality standard requirements as per PPB and WHO-GMP norms. This certification has opened the Kenyan markets for the Company products. The Company has filed 28 product dossiers for its range of Cephalosporin, Carbapenem and Oncology formulations for registration in Kenya, out of which 8 products have already been registered. The Company had tied up with one of the leading pharmaceutical distributor of Kenya and the first order for the territory has been successfully executed in the second quarter. The Company is expecting a healthy contribution to export sales from this territory11 Aug · Updates
Company has successfully launched its fourth Research Product, a Fixed Dose Combination of Cephalosporin with aminoglycoside under the Brand name "TOBRACEF" in Domestic Market for the first time golbally. The Drug Controller General of India had accorded its approval to Venus Remedies for launch of the fourth innovative product developed by Venus Research Centre, after completion of its multi-centred Phase III Clinical Trials and all related studies in March 2008. Tobracef, a brand launched by the marketing division of the Company, is a god send for APE/Cystic Fibrosis patients being the only solution for the treatment of life threatening infections caused by P. Aeruginosa / MRSA in these patients. The PSD division is targeting to fast penetrate the INR 2 billion domestic market and is expected to build this brand as a segment leader within 2 years of its launch. There are approximately 50 patent applications in process in 50 countries across the globe for this wonderful product and the Company is in talks for out-licencing of this product in US and other regulated markets of the world.7 Aug · Updates
Company's both Oncology manufacturing facilities, Oncology Liquid and Lyophilized, have been accredited with the European GMP certification, a landmark achievement, paving the way for the Company's immediate entry into regulated markets of Europe. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Aug · Change in registered office
Registered Office of the Company has been shifted within the same city from S.C.O. 39, Madhya Marg, Sector 26, Chandigarh to S.C.O. 857, Cabin No. 10, 2nd Floor, N.A.C. Manimajra, Chandigarh-160101 w.e.f. July 29, 2008 and in this regard Form-18 also has been filed with Register of Companies.
Jul 2008
29 Jul · Dividend
Board meeting held on July 29, 2008: (1) Approved enhancement of remuneration of working directors. (2) recommended a dividend @ of 40% for the financial year ended March 31, 2008 subject to approval of the same by shareholders at the Annual General Meeting. (3) Approved Change of Registered Office within the same city from S.C.O.39, Madhya Marg, Sector 26, Chandigarh to S.C.O. 857, Cabin No.10, 2nd Floor, N.A.C. Manimajra, Chandigarh-160101. (4) The Board also decided that Register of Members and Share Transfer Books shall remain closed from September 16, 2008 to September 22, 2008 (both days inclusive) for the purpose of Annual General Meeting and for the purpose of determining of entitlement to dividend.21 Jul · Board meeting
To inter alia consider and approve: 1) Unaudited Financial Results (Provisional) for the quarter ended June 30, 2008, 2) Annual Accounts of the Company for the year ended March 31, 2008, 3) Recommendation of dividend for the year 2007-2008, 4) Fix the Date of Annual General Meeting, 5) Enhancement in remuneration of working directors, 6) Change of Registered Office within the same city, 7) Any other business with the permission of the Chair.
May 2008
22 May · Management
Ms. Amarjeet Kaur, Company Secretary has been appointed as Compliance Officer as Ms. Monika Bisht, Company Secretary has resigned from the Company
Apr 2008
30 Apr · Voluntary Delisting
Equity shares of the Company have been delisted from the Ludhiana Stock Exchange Ltd. under voluntary delisting w.e.f. 25.02.2008.16 Apr · Board meeting
Meeting on 29 Apr 2008: “Unaudited Financial Results for the qtr ended March 31, 2008”
Mar 2008
31 Mar · Updates
"The Company's manufacturing facilities have been approved by the G.F.T.O of Syria for manufacturing and exporting its products to Syria". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Mar · Updates
Company's IPR Department has filed its 7th Patent Application with the Indian Patent Office for a novel, safe, low dose, non-irritating, highly efficacious and physiologically compatible antibiotic for the treatment of bacterial/ multi-bacterial infections in children. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.3 Mar · Updates
"The Drug Controller General of India has granted its approval to Venus Remedies for launch of its fourth innovative R&D developed product, Fixed Dose combination Drug of latest generation Cephalosporin with an Amino-glycoside, after completion of its Clinical Trials and all related studies. This Premium Product shall launched by Venus for the first time in the World very shortly". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2008
28 Jan · Allotment of Equity Shares
Board of Directors at its meeting held on January 28, 2008 have approved allotment of 22,495 equity shares under Employees Stock Options Scheme pursuant to exercise of options.15 Jan · Board meeting
To consider interalia Unaudited Financial Results (Provisional) for the quarter ended December 31, 2007 and to consider allotment of shares under Employees Stock Options Scheme (ESOP).15 Jan · Updates
"The Company has Inaugurated the Sixth and last phase of its INR 150 Crore expansion Project, its state of the art and hi-tech and elaborate research facility, "Venus Medicine Research Centre" at its Baddi Campus on January 14th, 2008." The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Jan · Updates
"The Company has been accredited with the European GMP Certification for its Cephalosporin and Carbapenem plants at Baddi, India, a rare and Most coveted certification for regulated markets." The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2007
3 Dec · Miscellaneous
"Maintaining its pace of IP creation,Venus's IPR Wing has successfully filed for Patent protection for Company 5th Research Product, "Treatment and Control of severe infections, including Cystic Fibrosis" in 47 countries across the globe where the product is planned to be launched by the Company". The further details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements)." For more details click here.
Nov 2007
26 Nov · Miscellaneous
"Leading on with its mission of world wide presence, Venus has successfully filed for Patent protection for its 4th Research Product, "Parenteral Combination Therapy for infective conditions with Drug Resistant Bacterium" in 48 countries across the globe, completing the National Phase of the 4th PCT well within the timeline." The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements)." For more details click here.19 Nov · Miscellaneous
The filing of Patent in individual countries of selection under the National Phase, of PCT application for the third research product of Venus Remedies Limited has been successfully completed in 48 countries for worldwide protection of the innovation in Patent 3 i.e "Fixed Dose Combination of a latest generation Cephalosporin with an Aminoglycoside" The Indian Patent for this innovative solution for treatment of life threatening infections caused by multi resistant p.aeruginosa or Acinetobactor species and / or MRSA was filed in December 2004 and the PCT in December 2005. The Company selected 48 countries with good market potential in the National Phase of the POT application for global Patent, including entire Europe, USA, Brazil, Japan, Canada, Australia and New Zealand, where it would be registering an launching this product. The product was launched in domestic market in October 2006 and is fast growing to be one of the leading multi-specialty, Critical Care brands. The potential market for this product across the globe is estimated to be around USD 1.00 billion
Oct 2007
15 Oct · Board meeting
Meeting on 22 Oct 2007: “Unaudited Financial Results for the Qtr ended Sept 30, 2007”
Sep 2007
14 Sep · Meeting
Annual General Meeting of Members of the company is scheduled to be held on September 24, 2007.11 Sep · Miscellaneous
"Venus Remedies Limited has got success in getting another of its Research Product, a FDC of Cephalosporin with an Amino-glycoside, registered in Ukraine and got regulatory approval for selling in this market". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2007
27 Aug · Business
Company has signed an agreement with M/s Pharma Match R&D B.V., a limited Company based at Amsterdam, Netherlands for jointly preparing, registering and marketing an EU E-CTD Dossier for a latest generation Carbapenem Injectible. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements). For more details click here.20 Aug · Dividend
August 20, 2007 that "The Board of Directors of Venus Remedies Limited at its meeting held today recommends a dividend @ of 30% for the financial year ended March 31, 2007 subject to the approval of the same by shareholders at the Annual General Meeting. The Board also decided that Register of Members and Share Transfer Books shall remain closed from 20th September 2007 to 24th September 2007 (both days inclusive) for the purpose of Annual General Meeting and for the purpose of determining of entitlement to dividend".17 Aug · Miscellaneous
"The newly completed manufacturing facilities of Venus Remedies Limited have successfully cleared yet another Plant Inspection by the M.C.A. of Zimbabwe and have been accredited with the Zimbabwe GMP certification". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Aug · Board meeting
To inter alia consider & approve Annual Accounts of the Company for the year ended March 31, 2007 & recommendation of Dividend for the same period.7 Aug · Miscellaneous
"The Phase IV of the prestigious Baddi Project of Venus Remedies has been completed". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2007
16 Jul · Board meeting
Meeting on 23 Jul 2007: “Unaudited financial results for quarter ended June 30, 2007”16 Jul · Miscellaneous
"Venus Remedies Limited has entered into another In-Licensing deal with a Chinese Inventor Company, and got the Exclusive Manufacturing and Marketing Rights for a latest generation Amino-glycoside formulation developed from a New Chemical Entity, for Indian markets". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 Jul · Miscellaneous
Venus Remedies Limited has got its Research Product, a FDC of Cephalosporin with a Beta-Lactamase, registered in Ukraine after getting all necessary regulatory approvals. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2007
25 Jun · Miscellaneous
Venus Remedies bagged the CNBC-TV-18's 'Emerging India Award' in the Pharma and Chemicals' category. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 Jun · Miscellaneous
Venus Remedies Limited has successfully cleared yet another Plant Inspection by the National Drug Authority of Uganda and has been accredited with the Uganda GMP certification, a prequalification for entering the Uganda market. The Manufacturing Plants of the Company, after having been GMP certified by the Ukranian GMP Inspectorate and INVIMA Inspecting authorities, have now been duly certified as "complying with the NDA requirements and WHO recommended current Good Manufacturing Practice Standards", by the Uganda National Drug Authorities. The facilities have been found suitable for manufacturing and exporting formulations to Uganda after three day long inspection of the Plants and systems by a team of 4 persons from Uganda NDA. This new milestone shall now allow Venus to fast penetrate the Uganda market and the Company is working passionately for getting its product basket registered in Uganda and to enter the market in a big way15 Jun · Miscellaneous
Venus Remedies Limited has successfully filed for Patent in 48 countries around the globe for the National Phase of its second PCT application for its Research Product, "Fixed Dose Combination of Latest Generation Cephalosporin with a Beta-Lactamase" The Company had filed the Indian Patent for this innovative, broad spectrum antibiotic in 2004 and the PCT in November 2005, having now entered in its National Phase the last step in the long chain of processes under PCT. The Company finalized and filed for Patent Protection of this novel formulation in 48 countries which have good market potential for this formulation, including the U.S, European Union, Japan, Middle-East, Brazil, Australia and New Zealand. The product has been a volume builder ever since it's launch in domestic markets and is growing at a fast pace. Worldwide also, this product has a market size worth more than 1.00 billion USD
May 2007
28 May · Miscellaneous
Venus Remedies Limited after freezing 49 countries around the globe for the National Phase of its first PCT application for its Research Product, "Non-Aqueous, Liquid Parenteral Formulation", has successfully completed the filing of Patent Applications in these 49 countries. The Company had filed its first Patent in November 2004 and now in its National Phase, the last step in the long chain of processes under PCT , the Company has finalized and filed for Patent Protection of this novel formulation in 49 countries where the Company is confident of having good market potential for this formulation, which includes the U.S, European Union, Japan, Middle East, Brazil, Australia, New Zealand amongst others.8 May · Miscellaneous
"The Phase III of the prestigious Baddi Project of Venus Remedies was recently inaugurated in April 2007". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2007
25 Apr · Board meeting
Board of Directors at its meeting held today on April 25, 2007 have approved allotment of 23,528 equity shares under Employees Stock Options Scheme pursuant to exercise of options granted. Further, Mr. Ashutosh Jain, Vice President, has been appointed as an Additional Director in whole time employment as Executive Director in charge of HR, Administration, regulatory Affairs, Legal and Projects".16 Apr · Board meeting
To consider interalia Unaudited financial Results (Provisional) for the quarter ended 31/3/2007 and to consider allotment of shares under Employees Stock Options Scheme (ESOS).
Mar 2007
12 Mar · Miscellaneous
Venus Remedies recently inaugurated the Phase II of its Baddi Project in March 2007. Two new dedicated Plants have been inaugurated for Carbapenem and Lyophilized Anti-cancer formulations, in injectible form, by the Company at its Baddi facility. The INR 100 Crore Baddi Project, to be completed in four phases by end of 2007, has provision for 8 dedicated plants for injectible formulations and a hi-tech R&D Centre. Out of these, the first phase, with dedicated plants for Cephalosporins and Oncology liquid injectibles, has been in operation since October 2005. The Company has created most modern, fully automatic manufacturing facilities, strictly as per international guidelines, which can match the best of facilities worldwide today. The new plants have been put on trial runs and the commercial production is to start from the first week of April. Venus is the first Company in India to have a dedicated plant for Carbapenems. Along with this, the Company has completely renovated its Unit I at Panchkula as per international Pharmaceutical guidelines and is now a unique facility in Glass Infusion manufacturing facilities in entire India. The Ultra-modern, fully automatic facility has been built up to international benchmarks and shall be manufacturing primarily, specialty, high-end infusions for export markets. The Company's manufacturing facilities are already GMP, WHO-GMP, ISO-9001, 14001 and 18001, Ukranian GMP and INVIMA GMP accredited and these additional facilities for exclusive lyophilized and Carbapenem formulations shall further bolster the Company's overseas market penetration.6 Mar · Meeting
Extra-ordinary General Meeting (EGM) of the members of the Company held on March 05, 2007 the following business was transacted unanimously: "Enhancement of the FlI investment limit in the company from 24% to 49% of the paid up equity capital of the company i.e. investments by Foreign Institutional Investors including their sub- accounts ("the FIIs"), in the shares of the Company, by direct investment, purchase or acquisition from the market or through private placement or conversion of convertible instrument under the Portfolio Investment Scheme under FEMA, on repatriation basis or otherwise subject to the condition that the total holding of all FIIs put together with their existing holding, if any, shall not exceed in aggregate 49 percent of the paid up equity share capital of the Company as may be applicable or such other maximum limit as may be prescribed from time to time, subject to necessary provisions and approvals. Further, without prejudice to the aforesaid overall limit of foreign investment in the capital of the Company, the investment by any single Foreign Institutional Investor (FII) shall not exceed 10 (ten) percent and all FIIs put together shall not exceed 49(forty nine) percent of the paid up equity capital of the Company from time to time
Feb 2007
19 Feb · Miscellaneous
Venus Remedies has got permission from the Drug Controller General of India for conducting Phase III Clinical Trials of the R&D product for treatment of Acute Pulmonary Exacerbation (APE) and Cystic Fibrosis, developed by its R&D wing. The Company has got the permission for conducting Multi-centered Clinical Trials for this new therapy, sure to provide the necessary relief to the APE patients across the globe. The new formulation, a Fixed Dose Combination Drug of latest generation Cephalosporin with an Amino-glycoside, has been immediately put on Clinical Trials at Centres across India immediately after receiving this permission. This product will be the only solution for the treatment of life threatening infections caused by Pseudomonas. Aeruginosa / MRSA in Cystic Firbrosis patients, thus helping in increasing their life span and would be launched for the first time in the world by Venus, targeting a market worth US $2.5 billion world wide. The formulation shall be ready for commercial launch in India by the last quarter of 2007. The Indian patent and PCT application for this sure shot therapy have already been filed by the IPR wing of the Company as the product will be launched for the first time globally. The Company is in an advanced stage of negotiations with some giants of Indian Pharmaceutical Industry, for the right placement of this product in the market15 Feb · Meeting
Notice Extra Ordinary General Meeting to be held on March 05, 2007. A copy of notice shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.7 Feb · Board meeting
Subject to the approval of shareholders in the Extra ordinary General Meeting to be held on March 5, 2007, the Board of Directors at its meeting held today on February 6, 2007 approved enhancing the FII investment limit in the company from 24% to 49% of the paid up equity capital of company.
Jan 2007
29 Jan · Board meeting
To consider inter alia enhancing the limit of FII's and NRI's in paid up equity capital of the Company and to consider holding of Extra Ordinary General Meeting for the approval of the Shareholders.8 Jan · Miscellaneous
Venus has filed its Sixth Patent Application to Indian Patent Office for the revolutionary Imaging Technology Product for Cancer Detection Product for Cancer Detection developed by its R&D department. Venus had in-licensed the technology for the Diagnostic Imaging for Detection of Solid Tumors in human body from University of Illinois, Chicago in June 2006. With the help of this technical knowledge, in collaboration with Oxygen Therapeutics Inc., a Chicago based Research Company, the Research and Development wing of the Company has successfully developed the innovative Product. It would be the first product of this kind i.e. a painless and cost effective method for detection of cancerous growth and is projected to have great response from the markets around the globe. This present invention can be easily used in low cost resource settting and would be a boon for the poor populations in developing economies. The Phase III clinical trials of this product are in process and it is expected to be launched in 2007. The Company is expecting to generate healthy sales volumes from this innovative Product4 Jan · Board meeting
Meeting on 15 Jan 2007: “Unaudited Financial Results for the quarter ended Dec 31, 06”